Dawn Blessing

Blessing has served as Vice President, Corporate Development since April 2014. She has 18 years of experience in biotechnology finance, business development, and alliance management. Over this period, Ms. Blessing has focused on programs for rare diseases and the application of genetic information to drug development. Before joining Audentes, Ms. Blessing served as Senior Director, Business Development and Alliance Management at 23andMe Inc., a personal genetics company. In her role at 23andMe, she led multiple genomic research programs with partners in the pharmaceutical industry. Prior to 23andMe, Ms. Blessing spent 8 years in Business and Corporate Development at BioMarin Pharmaceutical Inc., originating or leading successful licensing efforts in multiple therapeutic areas for rare diseases, including preclinical and clinical-stage products. Prior to her role in industry, Ms. Blessing was a Biotechnology Equity Research analyst at Cowen and Company LLC, UBS Securities LLC, and Needham and Company LLC.

Ms. Blessing earned a B.S. in Chemistry from the University of Richmond and a M.B.A. from Columbia Business School.

Dawn Blessing is the Vice President, Corporate Development at Audentes Therapeutics. With a background in Biotechnology, Dawn Blessing has a rich history of leadership and innovation.Dawn Blessing studied BS Chemistry at University of Richmond. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.